Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Theravance's telavancin meets Phase II endpoints

THRX said in the Phase II FAST trial, its telavancin ( TD-6424) met

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE